Design of sensitive monospecific and bispecific synthetic chimeric T cell receptors for cancer therapy

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Chimeric antigen receptor (CAR) T cell therapy shows promise for B cell malignancies.
• Tumor relapse occurs due to cancer cells with low or absent target antigens, evading CAR T cell detection.
• Enhanced sensitivity and multispecificity are needed to overcome CAR T cell evasion.

Purpose of the Study:

• Introduce a synthetic chimeric T cell receptor (ChTCR) with superior antigen sensitivity and bispecific targeting capabilities.
• Evaluate the efficacy of ChTCRs compared to CARs in combating tumor heterogeneity.
• Provide a strategy to prevent relapse in cancer patients.

Main Methods:

• Designed and constructed synthetic chimeric T cell receptors (ChTCRs).
• Compared ChTCRs and CARs for antigen sensitivity and signaling.
• Assessed bispecific ChTCRs (Bi-ChTCRs) in vivo models of heterogeneous tumors.
• Investigated the potential for targeting B cell and multiple myeloma antigens.

Main Results:

• ChTCRs demonstrated superior antigen sensitivity over CARs and other hybrid designs.
• ChTCRs replicate natural T cell receptor (TCR) structure, form immune synapses, and exhibit TCR-like signaling.
• Bispecific ChTCRs (Bi-ChTCRs) were more effective than bispecific CAR T cells in eradicating heterogeneous tumors in vivo.
• The Bi-ChTCR architecture is adaptable for targeting multiple antigens.

Conclusions:

• ChTCRs offer enhanced sensitivity and multispecificity for T cell-based cancer therapy.
• Bi-ChTCRs provide a robust strategy to combat tumor heterogeneity and prevent relapse.
• This technology has broad applicability for various B cell malignancies and multiple myeloma.